Higher Quality of Molecular Testing, an Unfulfilled Priority

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy et al. · Journal of Clinical Oncology · 2010 · 1.8K citations

Medicine, Oncology, Pharmacology +15

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley et al. · Journal of Thoracic Oncology · 2013 · 1.3K citations · Full text

Medicine, Molecular Medicine, Oncology +17

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 561 citations · Full text

Medicine, Genetics, Oncology +17

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley et al. · Journal of Molecular Diagnostics · 2013 · 461 citations

Medicine, Molecular Medicine, Oncology +17